Objective To investigate the levels and clinical significance of lipoprotein alpha[Lp(α)]and circulating oxidized low-density lipoprotein(ox-LDL)in calcific aortic valve disease(CAVD).Methods Totally,55 patients with CAVD(CAVD group)and 41 patients without valvular le-sions(control group),who were admitted to our hospital from August 2018 to December 2023,were select-ed for the study.The CAVD group was divided into 3 groups by dual source CT examination:mild calcifi-cation group,moderate calcification group and severe calcification group.Serum Lp(α)and ox-LDL levels were compared and analyzed in the CAVD and control groups before treatment.Serum Lp(α)and ox-LDL levels were compared and analyzed in the mild calcification group,moderate calcification group and severe calcification group.Serum Lp(α)and ox-LDL levels in the CAVD group were compared and analyzed be-fore and after treatment.Pearson's correlation was used to analyze the relationship between serum Lp(α)and ox-LDL and Agatston score.Results Patients in the CAVD group[409.20±134.55)mg/ml,(49.44±16.02)ng/ml]had significantly higher levels of Lp(α)and ox-LDL than those in the control group[(173.94±71.09)mg/L,(14.40±7.32)ng/ml,t=10.08,12.89,P<0.05].Patients in the severe calcification group[566.81±47.19)mg/L,(68.31±7.05)ng/ml]had significantly higher levels of Lp(α)and ox-LDL than moderate calcification group[(410.57±76.29)mg/L,(50.07± 6.96)ng/ml]and mild calcification group[(259.08±54.99)mg/L,(30.88±6.37)ng/ml,t=7.05,7.72,16.67,15.54,P<0.05].Pearson correlation analysis showed that serum Lp(α)and ox-LDL lev-els were positively correlated with Agatston score in CAVD patients(r=0.73,0.75,P<0.05).Lp(α)and ox-LDL levels were significantly lower in CAVD patients after treatment[273.51±93.99)mg/L,(31.66±8.70)ng/ml]than before treatment[(409.20±134.55)mg/L,(49.44±16.02)ng/ml,t=6.08,7.17,P<0.05].Conclusion Lp(α)and ox-LDL are involved in the development of CAVD,and changes in their levels correlate closely with the severity of the disease,making them good predictors for early diagnosis and monitoring and evaluation of CAVD.